On Friday, Cardinal Health earned a positive adjustment to its Relative Strength (RS) Rating, from 69 to 74.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves. See if Cardinal Health can continue to show renewed price strength and hit that benchmark.
When To Sell Stocks To Lock In Profits And Minimize Losses
While now is not an ideal time to jump in, see if the stock goes on to establish and enter a buying range in heavy volume.
Cardinal Health reported 9% earnings growth last quarter, while sales growth came in at -4%.
Cardinal Health earns the No. 3 rank among its peers in the Medical-Wholesale Drugs industry group. is the top-ranked stock within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
